trilostane has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auchus, RJ; Evaul, K; Li, R; Papari-Zareei, M; Sharifi, N | 1 |
| Hara, N; Hoshii, T; Ishizaki, F; Miyashiro, Y; Nishiyama, T; Takahashi, K; Takizawa, I | 1 |
2 other study(ies) available for trilostane and Prostatic Neoplasms
| Article | Year |
|---|---|
3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.
Topics: 17-Hydroxysteroid Dehydrogenases; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Nucleus; Dehydroepiandrosterone; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Male; Models, Biological; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Treatment Failure | 2010 |
Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells.
Topics: 3-Hydroxysteroid Dehydrogenases; Androgens; Cell Line, Tumor; Chromatography, Liquid; Dehydroepiandrosterone; Dihydrotestosterone; Enzyme Inhibitors; Humans; Male; Mass Spectrometry; Prostatic Neoplasms; Receptors, Androgen; Testosterone | 2010 |